EyePoint Pharmaceuticals Inc (EYPT)
17.50
-3.44
(-16.43%)
USD |
NASDAQ |
Apr 18, 16:00
17.50
0.00 (0.00%)
After-Hours: 20:00
EyePoint Pharmaceuticals Revenue (Quarterly): 14.03M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 14.03M |
| September 30, 2023 | 15.20M |
| June 30, 2023 | 9.105M |
| March 31, 2023 | 7.683M |
| December 31, 2022 | 10.53M |
| September 30, 2022 | 10.01M |
| June 30, 2022 | 11.56M |
| March 31, 2022 | 9.294M |
| December 31, 2021 | 11.54M |
| September 30, 2021 | 9.059M |
| June 30, 2021 | 9.013M |
| March 31, 2021 | 7.323M |
| December 31, 2020 | 7.131M |
| September 30, 2020 | 15.70M |
| June 30, 2020 | 4.122M |
| March 31, 2020 | 7.489M |
| December 31, 2019 | 8.633M |
| September 30, 2019 | 2.509M |
| June 30, 2019 | 7.21M |
| March 31, 2019 | 2.012M |
| September 30, 2018 | 0.486M |
| June 30, 2018 | 0.715M |
| March 31, 2018 | 0.928M |
| December 31, 2017 | 0.933M |
| September 30, 2017 | 0.385M |
| Date | Value |
|---|---|
| June 30, 2017 | 0.701M |
| March 31, 2017 | 0.59M |
| December 31, 2016 | 5.971M |
| September 30, 2016 | 0.277M |
| June 30, 2016 | 0.304M |
| March 31, 2016 | 0.324M |
| December 31, 2015 | 0.526M |
| September 30, 2015 | 0.466M |
| June 30, 2015 | 0.409M |
| March 31, 2015 | 0.328M |
| December 31, 2014 | 0.521M |
| September 30, 2014 | 25.31M |
| June 30, 2014 | 0.292M |
| March 31, 2014 | 1.992M |
| December 31, 2013 | 0.592M |
| September 30, 2013 | 0.597M |
| June 30, 2013 | 0.492M |
| March 31, 2013 | 0.513M |
| December 31, 2012 | 0.585M |
| September 30, 2012 | 0.553M |
| June 30, 2012 | 0.699M |
| March 31, 2012 | 0.538M |
| December 31, 2011 | 0.63M |
| September 30, 2011 | 1.659M |
| June 30, 2011 | 3.715M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
2.509M
Minimum
Sep 2019
15.70M
Maximum
Sep 2020
9.324M
Average
9.059M
Median
Sep 2021
Revenue (Quarterly) Benchmarks
| Apellis Pharmaceuticals Inc | 146.38M |
| Recursion Pharmaceuticals Inc | 10.62M |
| NovaBay Pharmaceuticals Inc | 3.727M |
| Palatin Technologies Inc | 2.034M |
| iBio Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -14.10M |
| Total Expenses (Quarterly) | 30.38M |
| EPS Diluted (Quarterly) | -0.32 |
| Enterprise Value | 714.90M |
| Gross Profit Margin (Quarterly) | 92.89% |
| Profit Margin (Quarterly) | -100.5% |
| Earnings Yield | -10.40% |
| Normalized Earnings Yield | -10.20 |